| 000 | 01814 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250515105633.0 | ||
| 264 | 0 | _c20080716 | |
| 008 | 200807s 0 0 eng d | ||
| 022 | _a1530-6860 | ||
| 024 | 7 |
_a10.1096/fj.07-101394 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aPuissant, Alexandre | |
| 245 | 0 | 0 |
_aImatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol. _h[electronic resource] |
| 260 |
_bFASEB journal : official publication of the Federation of American Societies for Experimental Biology _cJun 2008 |
||
| 300 |
_a1894-904 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAntineoplastic Agents, Phytogenic |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 | _aBenzamides |
| 650 | 0 | 4 | _aCaspases |
| 650 | 0 | 4 |
_aCell Differentiation _xdrug effects |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCell Survival _xdrug effects |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImatinib Mesylate |
| 650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xdrug therapy |
| 650 | 0 | 4 |
_aPiperazines _xpharmacology |
| 650 | 0 | 4 |
_aPyrimidines _xpharmacology |
| 650 | 0 | 4 | _aResveratrol |
| 650 | 0 | 4 |
_aStilbenes _xpharmacology |
| 700 | 1 | _aGrosso, Sebastien | |
| 700 | 1 | _aJacquel, Arnaud | |
| 700 | 1 | _aBelhacene, Nathalie | |
| 700 | 1 | _aColosetti, Pascal | |
| 700 | 1 | _aCassuto, Jill-Patrice | |
| 700 | 1 | _aAuberger, Patrick | |
| 773 | 0 |
_tFASEB journal : official publication of the Federation of American Societies for Experimental Biology _gvol. 22 _gno. 6 _gp. 1894-904 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1096/fj.07-101394 _zAvailable from publisher's website |
| 999 |
_c17751273 _d17751273 |
||